Source:http://linkedlifedata.com/resource/pubmed/id/12220625
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1-3
|
pubmed:dateCreated |
2002-9-10
|
pubmed:abstractText |
The two known mechanisms for telomere maintenance in eukaryocytes are telomerase in telomerase-positive cells and alternative lengthening of telomeres (ALT) in telomerase-negative cells. We report here that telomere maintenance in the telomerase-positive human ovarian SKOV-3 cells was not affected by inhibition of telomerase. For comparison, the effect of telomerase inhibitors on telomere maintenance in another telomerase-positive cell line (i.e. human pharynx FaDu cells) and the telomerase-negative human osteosarcoma Saos-2 cells was examined. Telomerase activity was measured using a modified telomeric repeat amplification protocol and telomere length was measured using a solution hybridization-based method and fluorescence in situ hybridization. A reverse transcriptase inhibitor (3'-azido-deoxythymidine or AZT) and an antisense against a component of human telomerase RNA (antisense hTR) were used to inhibit telomerase. FaDu and SKOV-3 cells showed comparable baseline telomerase activity. Telomerase activity in both cells was inhibited about equally by AZT (maximal inhibition of approximately 80%) and by expression of antisense hTR (complete inhibition in SKOV-3 cells and maximal inhibition of approximately 80% in FaDu cells). However, treatment with telomerase inhibitors resulted in approximately 50% telomere shortening in FaDu cells but had no effect on SKOV-3 nor Saos-2 cells. SKOV-3 cells did not show the characteristic features of ALT (i.e. heterogeneous telomere length and promyelocytic leukemia bodies), whereas these ALT features were observed in Saos-2 cells. Collectively, these results suggest the existence of a telomerase-independent mechanism of telomere maintenance in the telomerase-positive SKOV-3 cells.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0014-5793
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
11
|
pubmed:volume |
527
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
10-4
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:12220625-Cells, Cultured,
pubmed-meshheading:12220625-Enzyme Inhibitors,
pubmed-meshheading:12220625-Female,
pubmed-meshheading:12220625-Humans,
pubmed-meshheading:12220625-Oligonucleotides, Antisense,
pubmed-meshheading:12220625-Osteosarcoma,
pubmed-meshheading:12220625-Ovary,
pubmed-meshheading:12220625-Pharynx,
pubmed-meshheading:12220625-Telomerase,
pubmed-meshheading:12220625-Telomere,
pubmed-meshheading:12220625-Zidovudine
|
pubmed:year |
2002
|
pubmed:articleTitle |
Telomere maintenance in telomerase-positive human ovarian SKOV-3 cells cannot be retarded by complete inhibition of telomerase.
|
pubmed:affiliation |
College of Pharmacy, The Ohio State University, 500 West 12th Avenue, Columbus, OH 43210, USA.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|